The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs
Open accessAbstract
Transthyretin-cardiac amyloidoses (ATTR-CA) are an underdiagnosed but increasingly recognized cause of heart failure. Extracellular deposition of fibrillary proteins into tissues due to a variety of inherited transthyretin mutations in ATTRm or due to advanced age in ATTRwt eventually leads to organ failure. In the heart, amyloid deposition causes diastolic dysfunction, restrictive cardiomyopathy with progressive loss of systolic function, arrhythmias, and heart failure. While traditional treatments have consisted of conventional heart failure management and supportive care for systemic symptoms, numerous disease-modifying therapies have emerged over the past decade. From organ transplantation to transthyretin stabilizers (diflunisal, tafamidis, AG-1), TTR silencers (ALN-ATTR02, ISIS-TTR(Rx)), and degraders of amyloid fibrils (doxycycline/TUDCA), the potential for effective transthyretin amyloid therapy is greater now than ever before. In light of these multiple agents under investigation in human clinical trials, clinicians should be familiar with the systemic cardiac amyloidoses, their differing pathophysiology, natural histories, and unique treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 1×
“RNA interference (RNAi) has emerged as an endogenous cellular mechanism for controlling gene expression in which small interfering RNAs (siRNAs) bound to the RNA-induced silencing complex (RISC) mediates the cleavage of target messenger RNA (mRNA) [94, 95].”
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006) · BMJ · doi:10.1136/bmj.332.7553.1302 · Cited by 1,445
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial
Coelho, T., Maia, L. F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordeneuve, V., Lozeron, P., Suhr, O. B., Campistol, J. M., Conceição, I. M., Schmidt, H. H.-J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661eb1 · Cited by 816
Diagnosis and Management of the Cardiac Amyloidoses
Falk, R. H. (2005) · Circulation · doi:10.1161/circulationaha.104.489187 · Cited by 791
Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types
Rapezzi, C., Merlini, G., Quarta, C. C., Riva, L., Longhi, S., Leone, O., Salvi, F., Ciliberti, P., Pastorelli, F., Biagini, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843334 · Cited by 774
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade
Bulawa, C. E., Connelly, S., DeVit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J., Powers, E. T., Wiseman, R. L., Foss, T. R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121005109 · Cited by 742
Repurposing Diflunisal for Familial Amyloid Polyneuropathy: A Randomized Clinical Trial
Berk, J. L., Suhr, O. B., Obici, L., Sekijima, Y., Zeldenrust, S. R., Yamashita, T., Heneghan, M. A., Gorevic, P. D., Litchy, W. J., Wiesman, J. F., et al. (2013) · JAMA · doi:10.1001/jama.2013.283815 · Cited by 708
Bokhari, S., Castaño, A., Pozniakoff, T., Deslisle, S., Latif, F., & Maurer, M. S. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.000132 · Cited by 622
Self-citationHolmgren, G., Steen, L., Suhr, O., Ericzon, B.-G., Groth, C.-G., Andersen, O., Wallin, B. G., Seymour, A., Richardson, S., Hawkins, P. N., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)93127-m · Cited by 579
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes, N. A. M., Freedman, R. A., Gettes, L. S., Gillinov, A. M., Gregoratos, G., Hammill, S. C., Hayes, D. L., et al. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.04.014 · Cited by 552
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Pepys, M. B., Herbert, J., Hutchinson, W. L., Tennent, G. A., Lachmann, H. J., Gallimore, J. R., Lovat, L. B., Bartfai, T., Alanine, A., Hertel, C., et al. (2002) · Nature · doi:10.1038/417254a · Cited by 540
Page, J., & Henry, D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.6.777 · Cited by 517
Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes, N. A. M., Freedman, R. A., Gettes, L. S., Gillinov, A. M., Gregoratos, G., Hammill, S. C., Hayes, D. L., et al. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2008.04.015 · Cited by 468
Koyama, J., Ray-Sequin, P. A., & Falk, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000068313.67758.4f · Cited by 445
Holmgren, G., Steen, L., Ekstedt, J., Groth, C., Ericzon, B. ‐., Eriksson, S., Andersen, O., Karlberg, I., Nordén, G., Nakazato, M., et al. (1991) · Clinical Genetics · doi:10.1111/j.1399-0004.1991.tb03085.x · Cited by 396
Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome
Pinney, J. H., Whelan, C. J., Petrie, A., Dungu, J., Banypersad, S. M., Sattianayagam, P., Wechalekar, A., Gibbs, S. D. J., Venner, C. P., Wassef, N., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000098 · Cited by 372
Ng, B., Connors, L. H., Davidoff, R., Skinner, M., & Falk, R. H. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1425 · Cited by 367
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Transthyretin-related amyloidoses and the heart: a clinical overview
Rapezzi, C., Quarta, C. C., Riva, L., Longhi, S., Gallelli, I., Lorenzini, M., Ciliberti, P., Biagini, E., Salvi, F., & Branzi, A. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.67 · Cited by 350
Quarta, C. C., Solomon, S. D., Uraizee, I., Kruger, J., Longhi, S., Ferlito, M., Gagliardi, C., Milandri, A., Rapezzi, C., & Falk, R. H. (2014) · Circulation · doi:10.1161/circulationaha.113.006242 · Cited by 345
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Bodin, K., Ellmerich, S., Kahan, M. C., Tennent, G. A., Loesch, A., Gilbertson, J. A., Hutchinson, W. L., Mangione, P. P., Gallimore, J. R., Millar, D. J., et al. (2010) · Nature · doi:10.1038/nature09494 · Cited by 341
Coelho, T., Maurer, M. S., & Suhr, O. B. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.754348 · Cited by 339
Self-citationJohnson, S. M., Connelly, S., Fearns, C., Powers, E. T., & Kelly, J. W. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.060 · Cited by 328
Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis
Feng, D., Edwards, W. D., Oh, J. K., Chandrasekaran, K., Grogan, M., Martinez, M. W., Syed, I. I., Hughes, D. A., Lust, J. A., Jaffe, A. S., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.697763 · Cited by 305
Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis
Feng, D., Syed, I. S., Martinez, M., Oh, J. K., Jaffe, A. S., Grogan, M., Edwards, W. D., Gertz, M. A., & Klarich, K. W. (2009) · Circulation · doi:10.1161/circulationaha.108.785014 · Cited by 283
Sekijima, Y., Dendle, M. A., & Kelly, J. W. (2006) · Amyloid · doi:10.1080/13506120600960882 · Cited by 268
Ruberg, F. L., Maurer, M. S., Judge, D. P., Zeldenrust, S., Skinner, M., Kim, A. Y., Falk, R. H., Cheung, K. N., Patel, A. R., Pano, A., et al. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.04.015 · Cited by 261
Self-citationKristen, A. V., Dengler, T. J., Hegenbart, U., Schonland, S. O., Goldschmidt, H., Sack, F.-U., Voss, F., Becker, R., Katus, H. A., & Bauer, A. (2008) · Heart Rhythm · doi:10.1016/j.hrthm.2007.10.016 · Cited by 254
Digoxin sensitivity in amyloid cardiomyopathy.
Rubinow, A., Skinner, M., & Cohen, A. S. (1981) · Circulation · doi:10.1161/01.cir.63.6.1285 · Cited by 243
Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study
Obici, L., Cortese, A., Lozza, A., Lucchetti, J., Gobbi, M., Palladini, G., Perlini, S., Saraiva, M. J., & Merlini, G. (2012) · Amyloid · doi:10.3109/13506129.2012.678508 · Cited by 231
Adamski-Werner, S. L., Palaninathan, S. K., Sacchettini, J. C., & Kelly, J. W. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030347n · Cited by 230
SUHR, O., DANIELSSON, Å., HOLMGREN, G., & STEEN, L. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb01106.x · Cited by 209
Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis
Ihse, E., Ybo, A., Suhr, O., Lindqvist, P., Backman, C., & Westermark, P. (2008) · The Journal of Pathology · doi:10.1002/path.2411 · Cited by 209
Cyclooxygenase 2 inhibitors: discovery, selectivity and the future
Marnett, L. J., & Kalgutkar, A. S. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01385-1 · Cited by 205
Miller, S. R., Sekijima, Y., & Kelly, J. W. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700059 · Cited by 198
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., Rappley, I., Vogel, H., Liedtke, M., Witteles, R. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300761110 · Cited by 198
Pathogenesis of NSAID-induced gastroduodenal mucosal injury
Wallace, J. L. (2001) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2001.0229 · Cited by 196
Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis
LIN, G., DISPENZIERI, A., KYLE, R., GROGAN, M., & BRADY, P. A. (2013) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12123 · Cited by 188
Cardoso, I., Martins, D., Ribeiro, T., Merlini, G., & Saraiva, M. J. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-74 · Cited by 184
Pepys, M. B., Dash, A. C., Munn, E. A., Feinstein, A., Skinner, M., Cohen, A. S., Gewurz, H., Osmand, A. P., & Painter, R. H. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91260-0 · Cited by 173
Diflunisal for ATTR Cardiac Amyloidosis
Castaño, A., Helmke, S. T., Alvarez, J., Delisle, S., & Maurer, M. S. (2012) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2012.00303.x · Cited by 164
Self-citationCardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities
Falk, R. H., Rubinow, A., & Cohen, A. S. (1984) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(84)80436-2 · Cited by 159
Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model
Cardoso, I., & Saraiva, M. J. (2006) · The FASEB Journal · doi:10.1096/fj.05-4509com · Cited by 158
Progression of transthyretin amyloid neuropathy after liver transplantation
Liepnieks, J. J., Zhang, L. Q., & Benson, M. D. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15d4 · Cited by 158
Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
Varr, B. C., Zarafshar, S., Coakley, T. R., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L., & Witteles, R. M. (2013) · Heart Rhythm · doi:10.1016/j.hrthm.2013.10.026 · Cited by 156
Tojo, K., Sekijima, Y., Kelly, J. W., & Ikeda, S. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.08.014 · Cited by 153
Connors, L. H., Prokaeva, T. B., Lim, A., Théberge, R., Falk, R. H., Doros, G. D., Berg, A. M., Costello, C. E., O’Hara, C., Seldin, D. C., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.08.006 · Cited by 151
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides
Benson, M. D., Kluve‐Beckerman, B., Zeldenrust, S. R., Siesky, A. M., Bodenmiller, D. M., Showalter, A. D., & Sloop, K. W. (2006) · Muscle & Nerve · doi:10.1002/mus.20503 · Cited by 150
Digoxin sensitivity in amyloid cardiomyopathy.
ARubinow, MSkinner, & SCohen, A. (1981) · Circulation · Cited by 149
Merlini, G., Planté‐Bordeneuve, V., Judge, D. P., Schmidt, H., Obici, L. P., Perlini, S., Packman, J., Tripp, T. J., & Grogan, D. R. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9512-x · Cited by 141
Self-citationAckermann, E. J., Guo, S., Booten, S. L., Alvarado, L., Benson, M. D., Hughes, S. G., & Monia, B. P. (2012) · Amyloid · doi:10.3109/13506129.2012.673140 · Cited by 139
Biochemical Basis for Depressed Serum Retinol Levels in Transthyretin-deficient Mice
van Bennekum, A. M., Wei, S., Gamble, M. V., Vogel, S., Piantedosi, R., Gottesman, M., Episkopou, V., & Blaner, W. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008091200 · Cited by 136
Liepnieks, J. J., & Benson, M. D. (2007) · Amyloid · doi:10.1080/13506120701614032 · Cited by 132
ECHOVIRUS TYPE 30 AND MENINGITIS
SIMPSON, C. A. (1964) · The Lancet · doi:10.1016/s0140-6736(64)91939-7 · Cited by 124
Revised transthyretin Ile 122 allele frequency in African-Americans
Jacobson, D. R., Pastore, R. D., Pool, S., Malendowicz, S. L., Kane, I., Shivji, A., Embury, S. H., Ballas, S. K., & Buxbaum, J. N. (1996) · Human Genetics · doi:10.1007/s004390050199 · Cited by 114
Steen, L., & Ek, B. (1983) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1983.tb08613.x · Cited by 101
Prophylactic pacemaker implantation in familial amyloid polyneuropathy
Algalarrondo, V., Dinanian, S., Juin, C., Chemla, D., Bennani, S. L., Sebag, C., Planté‐Bordeneuve, V., Guludec, D. L., Samuel, D., Adams, D., et al. (2012) · Heart Rhythm · doi:10.1016/j.hrthm.2012.02.033 · Cited by 97
Heart complications in familial transthyretin amyloidosis: impact of age and gender
Hörnsten, R., Pennlert, J., Wiklund, U., Lindqvist, P., Jensen, S. M., & Suhr, O. B. (2010) · Amyloid · doi:10.3109/13506129.2010.483114 · Cited by 92
King, D. L., Coffin, L. E.-K., & Maurer, M. S. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)01944-7 · Cited by 91
Self-citationPotent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity
Alhamadsheh, M. M., Connelly, S., Cho, A., Reixach, N., Powers, E. T., Pan, D. W., Wilson, I. A., Kelly, J. W., & Graef, I. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002473 · Cited by 86
Cardiac Amyloidosis: Two Cases with Digitalis Sensitivity
Cassidy, J. T. (1961) · Annals of Internal Medicine · doi:10.7326/0003-4819-55-6-989 · Cited by 84
Bonaïti, B., Olsson, M. B., Hellman, U., Suhr, O. B., Bonaïti‐Pellié, C., & Planté‐Bordeneuve, V. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.36 · Cited by 83
Transthyretin Cardiac Amyloidoses in Older North Americans
Dharmarajan, K., & Maurer, M. S. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03868.x · Cited by 80
Self-citationGivens, R. C., Russo, C., Green, P., & Maurer, M. S. (2013) · Aging Health · doi:10.2217/ahe.13.10 · Cited by 71
Self-citationGustafsson, S., Ihse, E., Henein, M. Y., Westermark, P., Lindqvist, P., & Suhr, O. B. (2012) · Transplantation · doi:10.1097/tp.0b013e31824b3749 · Cited by 69
Suhr, O. B., Lindqvist, P., Olofsson, B., Waldenström, A. P., & Backman, C. (2006) · Amyloid · doi:10.1080/13506120600876849 · Cited by 68
Non-steroidal anti-inflammatory drugs and the continuum of renal dysfunction.
Epstein, M. (2002) · PubMed · Cited by 55
Endothelial dysfunction precedes C‐fiber abnormalities in primary (AL) amyloidosis
Berghoff, M., Kathpal, M., Khan, F., Skinner, M. M., Falk, R. H., & Freeman, R. L. (2003) · Annals of Neurology · doi:10.1002/ana.10552 · Cited by 53
Jonsén, E., Suhr, O. B., Tashima, K., & Athlin, E. E. (2001) · Amyloid · doi:10.3109/13506120108993814 · Cited by 52
Dhoble, A., Khasnis, A. A., Olomu, A. B., & Thakur, R. K. (2009) · Clinical Cardiology · doi:10.1002/clc.20389 · Cited by 46
Wiklund, U., Hörnsten, R., Karlsson, M., Suhr, O. B., & Jensen, S. M. (2008) · Annals of Noninvasive Electrocardiology · doi:10.1111/j.1542-474x.2008.00228.x · Cited by 46
Vitreous involvement in familial amyloidotic neuropathy: a genealogical and genetic study
Sandgren, O., Drugge, U., Holmgren, G., & Sousa, A. (1991) · Clinical Genetics · doi:10.1111/j.1399-0004.1991.tb03117.x · Cited by 42
Evaluation of domino liver transplantations in Germany
Bolte, F. J., Schmidt, H., Becker, T., Braun, F., Pascher, A., Klempnauer, J. L., Schmidt, J., Nadalin, S., Otto, G., & Barreiros, A. P. (2013) · Transplant International · doi:10.1111/tri.12110 · Cited by 35
Cited by
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Self-citationCastaño, A., Narotsky, D. L., Hamid, N., Khalique, O. K., Morgenstern, R., DeLuca, A., Rubin, J., Chiuzan, C., Nazif, T., Vahl, T., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx350 · Cited by 726
Self-citationMaurer, M. S., Bokhari, S., Damy, T., Dorbala, S., Drachman, B. M., Fontana, M., Grogan, M., Kristen, A. V., Lousada, I., Nativi-Nicolau, J., et al. (2019) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006075 · Cited by 568
Self-citationAddressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Self-citation
Metadata
- Authors
- Castaño, A., Drachman, B. M., Judge, D., & Maurer, M. S.
- Venue
- Heart Failure Reviews
- Published
- 2014-11-19
- Volume
- 20
- Issue
- 2
- Pages
- 163-178
- ISSN
- 1382-4147 (ISSN-L)
- 1573-7322
- OpenAlex
- W2088038696
- Cited by
- 254
- References
- 78
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.